Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme
NCT04115761Phase 2Recruiting
- Sponsor
- Ever Supreme Bio-Technology
- Start
- Jun 2019
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ADCV01 in glioblastoma multiforme (GBM) (2 arms), sponsored by Ever Supreme Bio-Technology. Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2019; status: recruiting.
02
Drugs
ADCV01
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04115761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115761.